Serum cystatin C levels are negatively correlated with post-stroke cognitive dysfunction.
Mini-Mental State Examination
abnormal renal function
cognitive dysfunction
cystatin C
ischemic stroke
neural regeneration
neuroprotective effect
normal renal function
Journal
Neural regeneration research
ISSN: 1673-5374
Titre abrégé: Neural Regen Res
Pays: India
ID NLM: 101316351
Informations de publication
Date de publication:
May 2020
May 2020
Historique:
entrez:
14
11
2019
pubmed:
14
11
2019
medline:
14
11
2019
Statut:
ppublish
Résumé
Stroke is the leading cause of death and long-term disability worldwide, and cognitive impairment and dementia are major complications of ischemic stroke. Cystatin C (CysC) has been found to be a neuroprotective factor in animal studies. However, the relationship between CysC levels and cognitive dysfunction in previous studies has revealed different results. This prospective observational study investigated the correlation between serum CysC levels and post-stroke cognitive dysfunction at 3 months. Data from 638 patients were obtained from the China Antihypertensive Trial in Acute Ischemic Stroke (CATIS). Cognitive dysfunction was assessed using the Mini-Mental State Examination (MMSE) at 3 months after stroke. According to the MMSE score, 308 patients (52.9%) had post-stroke cognitive dysfunction. After adjusting for potential confounding factors, the odds ratio (95% CI) of post-stroke cognitive dysfunction for the highest quartile of serum CysC levels was 0.54 (0.30-0.98), compared with the lowest quartile. The correlation between serum CysC and cognitive dysfunction was modified by renal function status. We observed a negative linear dose-response correlation between CysC and cognitive dysfunction in patients with normal renal function (P
Identifiants
pubmed: 31719258
pii: NeuralRegenRes_2020_15_5_922_268928
doi: 10.4103/1673-5374.268928
pmc: PMC6990774
doi:
Banques de données
ClinicalTrials.gov
['NCT01840072']
Types de publication
Journal Article
Langues
eng
Pagination
922-928Subventions
Organisme : NIGMS NIH HHS
ID : U54 GM104940
Pays : United States
Déclaration de conflit d'intérêts
None
Références
Neurotox Res. 2015 Jul;28(1):1-7
pubmed: 25697425
Neural Regen Res. 2019 Oct;14(10):1755-1764
pubmed: 31169193
Stroke. 2017 Feb;48(2):436-444
pubmed: 27999137
Stroke. 2017 Sep;48(9):2368-2374
pubmed: 28801477
Biochemistry. 2004 May 11;43(18):5119-25
pubmed: 15122877
J Am Heart Assoc. 2018 Jan 6;7(1):
pubmed: 29306898
Int J Stroke. 2013 Jan;8(1):38-45
pubmed: 23280268
Stroke. 2010 Jun;41(6):1290-3
pubmed: 20378863
Stroke. 1989 Jul;20(7):864-70
pubmed: 2749846
Cerebrovasc Dis. 2010;30(1):7-14
pubmed: 20424439
Neurosci Lett. 2016 Jan 1;610:19-23
pubmed: 26520462
Kidney Int. 2011 Jul;80(1):17-28
pubmed: 21150873
Clin Chem Lab Med. 2010 Nov;48(11):1619-21
pubmed: 21034257
Am J Kidney Dis. 2001 Jan;37(1):79-83
pubmed: 11136171
Stroke. 2014 Nov;45(11):3337-42
pubmed: 25248911
Neurology. 2010 Nov 2;75(18):1608-16
pubmed: 21041784
J Psychiatr Res. 1975 Nov;12(3):189-98
pubmed: 1202204
PLoS One. 2010 Mar 23;5(3):e9819
pubmed: 20352108
Stroke. 2014 Oct;45(10):2887-93
pubmed: 25116878
Int J Stroke. 2016 Dec;11(9):1009-1019
pubmed: 27412188
J Gerontol A Biol Sci Med Sci. 2015 Jun;70(6):771-8
pubmed: 25362662
Neurology. 2001 Oct 9;57(7):1216-22
pubmed: 11591838
J Am Geriatr Soc. 2002 Apr;50(4):700-6
pubmed: 11982671
Neurology. 2000 Mar 14;54(5):1124-31
pubmed: 10720286
JAMA. 2014 Feb 5;311(5):479-89
pubmed: 24240777
Diabetes Care. 2015 Feb;38(2):206-12
pubmed: 25205141
Eur J Neurol. 2010 Mar;17(3):383-90
pubmed: 19832902
N Engl J Med. 2003 Mar 27;348(13):1215-22
pubmed: 12660385
Neuroscience. 2004;128(1):65-71
pubmed: 15450354
Neural Regen Res. 2018 Aug;13(8):1384-1389
pubmed: 30106050
Am J Kidney Dis. 2000 Jul;36(1):29-34
pubmed: 10873868
Acta Neurol Scand. 2017 Sep;136(3):187-194
pubmed: 27804110
J Clin Hypertens (Greenwich). 2005 Feb;7(2):102-9
pubmed: 15722655
J Neurol Neurosurg Psychiatry. 1994 Feb;57(2):202-7
pubmed: 8126506